Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The patients must be able and willing to give written informed consent~2. The patients will be adult (age ≥ 18 years and ≤ 79 years) males or females~3. The patients must be on stable, evidence-based therapy for heart failure~   \* Note: CRT or CRT-D are acceptable co-therapy, if placed \> 3 months before randomization or the investigator does not anticipate within 6 months after randomization~4. The patients will have a left ventricular ejection fraction equal to or less than 35% via echocardiography, cardiac catheterization, radionuclide scan, or magnetic resonance imaging (measured within the last 30 days)~5. The patients will have a left ventricular end diastolic dimension indexed to body surface area (LVEDDi) of 30 to 40mm/m2 (LVEDD/BSA) (measured within the last 30 days)~6. Patients must have symptomatic heart failure with a Peak VO2 of 9.0 - 14.5 ml/min/kg (performed using a bicycle ergometer). Patients must perform two CPX tests (within 30 days of randomization and performed at least 20 hours apart) that differ by no more than 15% in the observed value for Peak VO2 and have a mean value of 9.0 - 14.5 ml/min/kg from these two tests.~7. Patient's surgical risk must be considered reasonable and the evaluation of surgical risk should include review of coronary and left ventricular angiography~8. If female, the patients must be (a) post-menopausal, (b) surgically sterile, or (c) using adequate birth control and have a negative serum pregnancy test within 7 days prior to administration of study device~Exclusion Criteria:~1. Patients for whom it is planned to receive CABG, MVR, heart transplantation or LVAD within the next 6 months.~2. Patients presenting with cardiogenic shock.~3. Patients who have undergone a previous mid-sternotomy surgical procedure are excluded unless the surgeon's assessment is that the left sided limited thoracotomy is feasible and considered reasonable surgical risk.~4. Patients presenting with a restrictive cardiomyopathy such as due to amyloidosis, sarcoidosis, or hemochromatosis~5. Patient with a history of constrictive pericarditis~6. Patients with a Q wave myocardial infarction (MI) within the last 30 days~7. Patients with a recent history of stroke (within 60 days prior to the surgical procedure)~8. A left ventricular (LV) wall thickness of the LV free-wall, at the mid-ventricular level, of less than 8 mm (screening echocardiography must confirm a minimum wall thickness of 8 mm)~9. Patients with a serum creatinine \> 2.5 mg/dL~10. Clinically significant liver enzyme abnormalities, i.e., AST(SGOT) and ALT (SGPT) more than 2.5 times the upper limit of normal~11. History of severe COPD (i.e., FEV 1\< 1 liter or FEV1 \< 50% predicted)~12. The patients will not be receiving concurrently an investigational Product in another clinical trial or have received an investigational Product in another clinical trial in the 30 days prior to enrollment~13. A life expectancy of less than 1 year or any other condition that, in the opinion of the clinical investigator, might compromise any aspect of the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Algisyl-LVR (Type: EXPERIMENTAL): Algisyl-LVR™ device (implants) administered during a surgical procedure.
- Standard Medical Therapy (Type: ACTIVE_COMPARATOR): as per protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).